Vasant Narasimhan spent the first phase of his tenure simplifying Novartis. In 2026, the harder phase is visible: deciding how much capital to commit, and how quickly, to replenish the focused medicines company he created. The answer so far is an assertive combination of acquisitions, manufacturing investment and local research partnerships.
Novartis completed its approximately US$12 billion cash acquisition of Avidity Biosciences in February, gaining three late-stage neuromuscular programmes based on antibody-oligonucleotide conjugates. On 6 July it agreed to acquire Myricx Bio for US$1.1 billion upfront and as much as US$400 million in milestones, adding a preclinical antibody-drug conjugate platform built around a novel payload. In China, it has announced more than RMB3.3 billion in new Beijing and Shanghai investment while developing additional radioligand manufacturing capacity.
These are not isolated projects. Together they show Narasimhan using the balance sheet to buy modalities, expand physical infrastructure and deepen access to one of the industry’s most productive innovation markets. The approach may build the next growth cycle. It also pushes net debt higher, adds integration demands and asks shareholders to accept that several different capital commitments will mature on different timetables.
Narasimhan ranks third because Novartis has moved from strategic focus to capital intensity. Leadership in 2026 is no longer mainly about choosing therapeutic areas. It is about converting acquired science and Asian investment into risk-adjusted cash before financing cost and organisational complexity reduce the benefits of scale.
A strong year created room for a faster deal pace
Novartis ended 2025 with net sales of US$54.5 billion, operating income of US$17.6 billion and free cash flow of US$17.6 billion. That performance supplied ample capacity for acquisitions, dividends and repurchases. It also raised expectations that the focused model could sustain growth without recreating the conglomerate complexity Narasimhan had removed.
The first quarter of 2026 showed why management is willing to accelerate pipeline renewal. Sales were US$13.1 billion, down 5 per cent at constant currencies, while core operating income fell 14 per cent. Generic competition created a 14-percentage-point drag on sales growth, partly offset by 13 points from volume. Core margin declined 4.1 percentage points at constant currencies to 37.3 per cent.
Those numbers do not invalidate the portfolio. Several priority brands and launches continued to grow. They do, however, compress the time available for new assets to become material. The company reaffirmed guidance for low-single-digit sales growth and a low-single-digit decline in core operating income for 2026. Acquisitions may improve the medium-term outlook, but they increase near-term cash demands before contributing meaningful revenue.
Net debt illustrates the transition. It rose from US$21.9 billion at the end of 2025 to US$38.1 billion at the end of March 2026. During the quarter, Novartis reported US$12.5 billion of cash outflow for acquisitions of businesses and intangible assets, a US$6.2 billion dividend and US$1.9 billion used for treasury shares. The group remains highly cash-generative, but the margin for simultaneous capital choices has narrowed.
Avidity is a late-stage wager on delivery
Avidity gives Novartis access to a platform designed to deliver RNA therapeutics to muscle by linking oligonucleotides to antibodies. Its lead programmes address rare neuromuscular diseases, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. These markets have high unmet need and concentrated clinical expertise, but they also require convincing functional outcomes, long follow-up and carefully managed safety.
The strategic rationale is clear. Novartis already has capabilities in neuroscience, gene therapy and RNA-targeting medicines. A delivery platform that reaches muscle could extend that position and provide several product opportunities rather than a single asset. Management increased its expected 2024-to-2029 sales compound annual growth rate from 5 per cent to 6 per cent when it announced the transaction, excluding the effect of foreign exchange.
The price embeds confidence that late-stage data and approvals will arrive on schedule. For rare-disease assets, small changes in eligible patient numbers, treatment persistence or price can materially alter value. Manufacturing an antibody-oligonucleotide conjugate at commercial quality also requires coordination across complex components. Novartis must show that owning the platform creates development and production advantages large enough to justify paying for the entire company.
Integration should be selective. The specialist teams that built Avidity’s delivery technology need access to Novartis’s clinical, regulatory and commercial scale without being absorbed into slower decision cycles. Success will be visible in recruitment speed, manufacturing readiness and the quality of filings, not in the number of internal committees formed around the acquisition.
Myricx extends the strategy into earlier oncology risk
The proposed Myricx acquisition is smaller in cash terms but earlier and therefore more scientifically uncertain. Myricx is developing antibody-drug conjugates using inhibitors of N-myristoyltransferase as payloads. Its lead programmes target B7-H3 and HER2, two areas where many companies are seeking differentiated tumour killing with manageable toxicity.
Novartis is paying US$1.1 billion upfront for a platform that remains preclinical, with up to US$400 million tied to milestones. This gives the company control before human data are available. The potential benefit is lower entry cost than a validated late-stage oncology asset and the ability to shape development. The risk is that payload behaviour in patients differs from laboratory models, or that the competitive field advances faster than Myricx.
The transaction should therefore be evaluated as a portfolio of experiments. Management must define early stopping rules around therapeutic index, linker stability, target selection and manufacturability. The milestone structure provides some protection, but most of the headline consideration is upfront. Scientific novelty is valuable only if it produces an observable advantage over existing and emerging antibody-drug conjugates.
Avidity and Myricx also reveal the breadth of Narasimhan’s capital strategy. One deal buys late-stage neuromuscular programmes; the other buys a preclinical oncology payload. Diversification across modalities can improve the probability that something succeeds, but it demands different expertise and timelines. Novartis has to avoid treating acquisition volume as a proxy for pipeline quality.
China is becoming infrastructure, not just revenue
China generated US$4.2 billion of Novartis sales in 2025, about 8 per cent of the group total. The company describes it as its second-largest market. Yet the strategic importance now extends beyond product demand. Chinese biotechnology has become a major source of licensing opportunities, clinical recruitment and increasingly global-quality research.
In March 2026, Novartis announced more than RMB3.3 billion of investment: roughly RMB1.5 billion to expand its Beijing operation in Changping and RMB1.8 billion for a second phase at its Shanghai campus. It said that potential commitments to Chinese biotechnology companies since 2024 exceeded RMB80 billion. More than 100 clinical projects were active in the country, and from 2026 the group aims for Chinese regulatory submissions to occur at the same time as global filings.
Novartis is also investing in radioligand-therapy production. A facility in Haiyan, Zhejiang province, backed by about RMB600 million, is intended to become operational in 2027. Radioligand medicines have short and exacting supply chains because radioactive material loses potency over time. Local production is therefore not merely a cost decision; it determines how many patients can be reached reliably.
This infrastructure could create a powerful loop. Local research and licensing supply assets; Chinese trials generate evidence; synchronous filings reduce launch delay; domestic manufacturing supports delivery. The financial return depends on execution across all four stages. Capital can be trapped if regulatory access changes, price pressure intensifies or a facility is built ahead of demand.
Geopolitical and data risks also require active governance. Cross-border drug development involves patient data, biological samples, intellectual property and export controls. Novartis must design programmes that comply with Chinese and international requirements without isolating the local operation from global development. The objective is an integrated capability, not a parallel system that duplicates cost.
The buyback makes capital discipline more visible
Novartis is undertaking acquisitions and investment while maintaining shareholder returns, including a share-repurchase programme. Repurchases can be attractive when shares trade below management’s assessment of intrinsic value. They are less compelling if debt-funded or if they limit flexibility around high-return pipeline opportunities.
The company’s free cash flow gives Narasimhan room to do several things at once, but investors should examine sequencing. Avidity’s large cash price, Myricx’s upfront payment, Chinese infrastructure, dividends and buybacks all compete for the same cash generation. The right question is not whether Novartis can fund them in an accounting sense. It is whether the combined return exceeds the financing and opportunity cost.
Debt reduction will be an important signal. If operating cash flow brings leverage down quickly while priority brands continue growing, the 2026 deal sprint will look deliberate. If generic erosion persists, acquired programmes slip and repurchases continue at the same pace, financial flexibility could deteriorate. A strong credit profile should not become an excuse to postpone trade-offs.
What Narasimhan must prove next
The first proof point is operational: Avidity’s programmes need on-time data, regulatory progress and a credible manufacturing path. The second is scientific: Myricx must show in humans that its payload can widen the therapeutic window rather than merely add another mechanism to a crowded category. The third is regional: Chinese investment must shorten development and delivery timelines, not simply increase fixed cost.
Disclosure should match the scale of capital committed. Novartis should show how acquired assets affect research spending, provide specific milestones and explain the cash-flow path as debt falls. For China, it should distinguish firm transaction value from contingent milestone commitments and report whether synchronous submissions are actually reducing launch lag.
Narasimhan’s simplified Novartis created the capacity for this moment. The paradox is that success now requires adding controlled complexity: new modalities, acquired teams, specialised plants and deeper regional networks. His leadership will be measured by whether those additions operate as one capital system. If Avidity, Myricx and China produce evidence and cash on disciplined timetables, the 2026 spending will look like renewal. If they do not, strategic focus will have been preserved in name while diluted in economics.
